These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26463904)

  • 21. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
    van den Brink W; Sørensen P; Torup L; Mann K; Gual A;
    J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid-dependent error processing.
    Fellows-Smith J
    J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.
    Diot C; Eiden C; Roussin A; Batisse A; Boucher A; Chavant F; Daveluy A; Donadieu-Rigole H; Peyrière H;
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1539-40. PubMed ID: 26329380
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
    Milano G; Zavan V; Natta WM; Martelli A; Mattioli F
    J Clin Pharm Ther; 2016 Feb; 41(1):97-100. PubMed ID: 26714742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Place of the opioid system in biology and treatment of Alcohol Use Disorder].
    Nubukpo P
    Encephale; 2014 Dec; 40(6):457-67. PubMed ID: 25454364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
    Badalamenti VC; Buckley JW; Smith ET
    J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Benefits in reducing alcohol consumption: how nalmefene can help].
    Bendimerad P; Blecha L
    Encephale; 2014 Dec; 40(6):495-500. PubMed ID: 25454365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current strategies for the treatment of alcohol dependence in the United States.
    O'Malley SS
    Drug Alcohol Depend; 1995 Sep; 39 Suppl 1():S3-7. PubMed ID: 8565795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
    Lescut C; Gaboriau L; Carton L; Rolland B
    J Clin Psychopharmacol; 2017 Oct; 37(5):631-633. PubMed ID: 28806388
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacological profile and clinical findings of nalmefene (Selincro
    Tadori Y
    Nihon Yakurigaku Zasshi; 2020; 155(2):113-119. PubMed ID: 32115477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid peptides and primary biliary cirrhosis.
    Thornton JR; Losowsky MS
    BMJ; 1988 Dec; 297(6662):1501-4. PubMed ID: 3147046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
    Mason BJ; Ritvo EC; Morgan RO; Salvato FR; Goldberg G; Welch B; Mantero-Atienza E
    Alcohol Clin Exp Res; 1994 Oct; 18(5):1162-7. PubMed ID: 7847600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
    Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
    Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does naltrexone affect craving in abstinent opioid-dependent patients?
    Dijkstra BA; De Jong CA; Bluschke SM; Krabbe PF; van der Staak CP
    Addict Biol; 2007 Jun; 12(2):176-82. PubMed ID: 17508990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid Withdrawal Precipitated by Long-Acting Antagonists.
    Kunzler NM; Wightman RS; Nelson LS
    J Emerg Med; 2020 Feb; 58(2):245-253. PubMed ID: 32005608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
    Barrio P; Ortega L; Guardia J; Roncero C; Yuguero L; Gual A
    Clin Drug Investig; 2018 Feb; 38(2):147-155. PubMed ID: 29080208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obviation of opioid withdrawal syndrome by concomitant administration of naltrexone in microgram doses: two psychonautic bioassays.
    Ott J
    J Psychoactive Drugs; 2006 Mar; 38(1):101-5. PubMed ID: 16681181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges to antagonist blockade during sustained-release naltrexone treatment.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Gossop M; Hegstad S; Kristensen Ø; Waal H
    Addiction; 2010 Sep; 105(9):1633-9. PubMed ID: 20707781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.